VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Aims & design of the EXCALIBER-RRM study

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the design and aims of EXCALIBER-RRM (NCT04975997), a Phase III study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab versus daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter